FTC rules on preterm infant formula ads

Summary#

This bill directs the Federal Trade Commission (FTC) to investigate advertising and marketing of preterm infant formula, report to Congress within one year, and then write rules banning unfair or deceptive advertising practices for those products. The rules must address ads that leave out possible health risks or that fail to explain differences between human milk/human milk–based fortifiers and bovine-based fortifiers. The stated policy goal is to make sure families have accurate information about preterm infant feeding and to protect preterm infants and their families.

• Main change: FTC must investigate marketing of preterm infant formula, report in 1 year, and issue regulations within 18 months after that report to prohibit unfair or deceptive marketing.
• Required topics for the investigation and rules: whether marketing omits labeling about potential health risks and whether it omits differences (benefits and drawbacks) between human milk/human milk–based fortifiers and bovine-based fortifiers.
• Enforcement: Violations of the new FTC rules would be treated as violations of the FTC Act and enforceable by the FTC with existing powers and penalties.
• Definitions: The bill defines “preterm infant” (born before 37 weeks or low birth weight) and “preterm infant formula” as formulas that are exempt under a specific federal food law provision and are intended for preterm infants.
• Sense of Congress: The bill states reasons for action, including concerns about necrotizing enterocolitis (NEC) and the importance of families’ ability to seek compensation; those statements do not by themselves change law.

What it means for you#

• Manufacturers and importers of preterm infant formula

  • They would be subject to new FTC rules banning unfair or deceptive advertising about preterm infant formula.
  • Ads and marketing materials could be required to include certain risk information or clear comparisons between types of fortifiers, depending on how the FTC writes the rules.
  • They would face FTC enforcement and penalties if found to violate the new rules.

• Parents and families of preterm infants

  • The bill aims to make advertising clearer about possible health risks and differences among feeding options. This could mean more information in marketing and labeling in the future.
  • The bill’s “sense of Congress” says families should be able to seek compensation when harm occurs, but the bill does not itself change litigation rights.

• Federal Trade Commission

  • Must carry out an investigation and produce a report within 1 year of enactment.
  • Must complete rulemaking to ban unfair or deceptive advertising practices within 18 months after delivering the report.
  • The investigation is exempt from the Paperwork Reduction Act (a federal paperwork review law), per the bill.

• Health care providers and hospitals

  • The bill does not directly change clinical rules or hospital practices. It could affect what information manufacturers provide to hospitals and clinicians through marketing and product materials.

• General public

  • If the FTC issues rules, consumers may see different or fuller information in ads and labels for preterm infant formula. The bill does not itself create any new consumer benefits until the FTC acts.

Expenses#

No publicly available information.

• The bill requires the FTC to conduct an investigation and later complete rulemaking; this would likely create administrative costs for the FTC (staff time, research, rulemaking process).
• Manufacturers may incur compliance costs to change labels, marketing materials, and training if the FTC requires additional disclosures.
• Enforcement of the new rules could involve FTC enforcement costs and legal costs for regulated entities; the bill does not provide any budget figures or cost estimates.

Proponents' View#

• The bill appears intended to make sure parents get complete and accurate information about feeding options for preterm infants.
• It highlights concerns about necrotizing enterocolitis (NEC) and the safety differences between human milk–based and bovine-based fortifiers; proponents may see clearer advertising as a way to reduce risk.
• Supporters may argue that FTC action can prevent misleading marketing practices and protect vulnerable infants and their families.
• The bill expresses that families should be able to seek compensation if harm occurs, which could be presented as strengthening consumer protections in principle.

Opponents' View#

• One concern is that the bill leaves many important details to the FTC rulemaking. It does not specify exact disclosures, so outcomes depend on how the FTC writes and enforces rules.
• The bill does not explain how the FTC rules will interact with existing food and drug labeling laws and agencies; coordination and overlap are unclear.
• The requirement is limited to advertising and marketing; it does not itself change clinical guidance, product approval, or private legal rights, despite the “sense of Congress” language.
• Compliance could impose costs on manufacturers and importers to change labeling and marketing materials, but the bill provides no cost estimates or funding to cover administrative work.
• The investigation exemption from the Paperwork Reduction Act could raise procedural concerns about oversight of data collection, but the bill does not explain the reason for that exemption.